Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.

The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.

AI-generated analysis. Not financial advice.

News Market Reaction – FATE

-2.46%

3 alerts

-2.46% News Effect

-$4M Valuation Impact

$144.17M Market Cap

4.25K Volume

On the day this news was published, FATE declined 2.46%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $144.17M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement RSUs granted: 7,260 shares Vesting period: 4 years Annual vesting rate: 25% per year +5 more

8 metrics

Inducement RSUs granted 7,260 shares Grant to one newly hired non-executive employee on April 1, 2026

Vesting period 4 years RSUs vest over four years, subject to continued employment

Annual vesting rate 25% per year 25% of RSU shares vest on each anniversary of grant date

New hires covered 1 employee Inducement award to one newly hired non-executive employee

Current share price $1.24 Price prior to publication of inducement award news

Price vs 52-week high -36.08% Distance from 52-week high of $1.9399 before this news

Price vs 52-week low 87.57% Above 52-week low of $0.6611 before this news

Market capitalization $139,516,151 Market value before this inducement announcement

Market Reality Check

Price: $2.25 Vol: Volume 707,061 is below 2...

low vol

$2.25 Last Close

Volume Volume 707,061 is below 20-day average of 1,454,112 (relative volume 0.49). low

Technical Price 1.24 is trading above 200-day MA at 1.16.

Peers on Argus

FATE was up 3.33% while closely rated biotech peers showed mixed moves (e.g., CR...

1 Up

FATE was up 3.33% while closely rated biotech peers showed mixed moves (e.g., CRBP up 5.5%, KALA down 9.44%). Momentum scanner only flagged IOBT, suggesting today’s action is stock-specific rather than a broad sector rotation.

Common Catalyst Multiple biotech names, including EQ, reported inducement grants under Nasdaq Listing Rule 5635(c)(4), highlighting routine equity-based hiring activity in the sector.

Historical Context

5 past events · Latest: Mar 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Inducement awards	Neutral	-4.8%	RSUs for three new non-executive hires under inducement equity plan.
Mar 03	Conference participation	Positive	+5.8%	Participation in Leerink Global Healthcare Conference with webcast and meetings.
Feb 26	Earnings and updates	Positive	+5.4%	Q4 and 2025 results with cash of $205.1M and lower operating expenses.
Feb 03	Inducement awards	Neutral	-0.9%	Stock options and RSUs granted to new hire under inducement equity plan.
Jan 05	Inducement awards	Neutral	+0.0%	Options and RSUs to multiple new hires with standard four-year vesting.

Pattern Detected

Recent inducement award announcements have generally coincided with muted or mixed price reactions, while earnings and conference participation saw modest positive moves.

Recent Company History

Over the last few months, FATE repeatedly disclosed inducement awards under Nasdaq Listing Rule 5635(c)(4), including grants on Jan 1, Feb 1, and Mar 2, 2026, all vesting over four years with 25% annual vesting. These routine HR-related updates produced small or mixed price moves. In contrast, the Feb 26, 2026 earnings and 10-K context showed improved expenses and cash runway, with shares rising after that update and around a Mar 9, 2026 conference appearance.

Market Pulse Summary

This announcement details a routine inducement grant of 7,260 RSUs vesting over four years under Nas...

Analysis

This announcement details a routine inducement grant of 7,260 RSUs vesting over four years under Nasdaq Listing Rule 5635(c)(4), consistent with FATE’s prior new-hire awards. In recent months the company has repeatedly used this structure while also reporting improved expense trends and a cash runway through 2027. Investors may track the scale and frequency of such equity grants alongside insider Form 4 activity and upcoming clinical or financial milestones.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement equity plan

4 terms

restricted stock units financial

"the Company granted restricted stock units (RSUs) representing 7,260 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The RSUs will vest over four years, with 25% of the shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employee ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement equity plan financial

"granted under the Company’s Amended and Restated Inducement Equity Plan"

An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.

AI-generated analysis. Not financial advice.

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com

FAQ

What did Fate Therapeutics (FATE) announce on April 1, 2026 about employee compensation?

Fate Therapeutics granted 7,260 RSUs to a newly hired non-executive employee as an inducement award. According to the company, the grant was approved by the Compensation Committee under its Amended and Restated Inducement Equity Plan and complies with Nasdaq Listing Rule 5635(c)(4).

How do the 7,260 RSUs granted by Fate Therapeutics (FATE) vest and when do vesting milestones occur?

The 7,260 RSUs vest over four years with 25% vesting on each anniversary of the April 1, 2026 grant. According to the company, vesting is contingent on the employees continuous employment through each anniversary vesting date.

Does the Fate Therapeutics (FATE) RSU grant require any shareholder approval under Nasdaq rules?

The RSU grant was made as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4), which permits certain equity awards without prior shareholder approval. According to the company, the award was approved by its Compensation Committee under its inducement plan.

Will the 7,260 RSU inducement awarded by Fate Therapeutics (FATE) likely cause material dilution?

The company disclosed a single award of 7,260 RSUs to a non-executive hire but did not state outstanding share count to quantify dilution. According to the company, the award is a standard inducement grant subject to four-year vesting and continuous employment.